Skip to main content

Clinical and Translational Oncology

Ausgabe 7/2024

Inhalt (26 Artikel)

Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

  • Open Access
  • REVIEW ARTICLE

Eva Ciruelos, Jose Ángel García-Sáenz, Joaquín Gavilá, Miguel Martín, César A. Rodríguez, Álvaro Rodríguez-Lescure

What’s new about the tumor microenvironment of urothelial carcinoma?

  • REVIEW ARTICLE

João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo

Towards stronger tobacco control policies to curb the smoking epidemic in Spain

  • Open Access
  • REVIEW ARTICLE

Mónica Pérez-Ríos, Jasjit Ahluwalia, Carla Guerra-Tort, Guadalupe García, Julia Rey-Brandariz, Nerea Mourino-Castro, Ana Teijeiro, Raquel Casal-Fernández, Iñaki Galán, Leonor Varela-Lema, Alberto Ruano-Ravina

Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

  • Open Access
  • REVIEW ARTICLE

Mónica Guillot Morales, Laura Visa, Elena Brozos Vázquez, Jaime Feliu Batlle, Parham Khosravi Shahi, Berta Laquente Sáez, Borja López de San Vicente Hernández, Teresa Macarulla, Regina Gironés Sarrió

Current approaches in glioblastoma multiforme immunotherapy

  • REVIEW ARTICLE

Marjan Aghajani, Nazila Jalilzadeh, Ali Aghebati-Maleki, Amirhossein Yari, Peyman Tabnak, Amirhossein Mardi, Hossein Saeedi, Leili Aghebati-Maleki, Behzad Baradaran

Surgical margins and prognosis of borderline and malignant phyllodes tumors

  • RESEARCH ARTICLE

Jialin Su, Shanling Liu, Gang Tu, Fangxuan Li, Jie Zhang, Lu Gan

On the need of in vivo verifications as quality control for intraoperative electron radiotherapy in breast cancer

  • RESEARCH ARTICLE

Carla Cases, Gabriela Oses, Antonio Herreros, Jordi Tarrats-Rosell, Sara Moreno, Meritxell Mollà

Criteria and indicators to evaluate quality of care in genitourinary tumour boards

  • RESEARCH ARTICLE

Javier Puente, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gómez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

  • Open Access
  • RESEARCH ARTICLE

Aylen Vanessa Ospina, Sergio Bolufer Nadal, José Luis Campo-Cañaveral de la Cruz, Jose Luis González Larriba, Ivan Macía Vidueira, Bartomeu Massutí Sureda, Ernest Nadal, Florentino Hernando Trancho, Antonio Álvarez Kindelán, Edel Del Barco Morillo, Reyes Bernabé Caro, Joaquim Bosch Barrera, Virginia Calvo de Juan, Joaquin Casal Rubio, Javier de Castro, Ángel Cilleruelo Ramos, Manuel Cobo Dols, Manuel Dómine Gómez, Santiago Figueroa Almánzar, Rosario Garcia Campelo, Amelia Insa Mollá, José Ramón Jarabo Sarceda, Unai Jiménez Maestre, Rafael López Castro, Margarita Majem, Alex Martinez-Marti, Elisabeth Martínez Téllez, David Sánchez Lorente, Mariano Provencio

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis

  • RESEARCH ARTICLE

Hanxiao Chen, Xiangjuan Ma, Jie Liu, Yu Yang, Yanhui He, Yong Fang, Liping Wang, Jian Fang, Jun Zhao, Minglei Zhuo

Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

  • Open Access
  • Research Article

Aranzazu Arias-Martinez, Eva Martínez de Castro, Javier Gallego, Virginia Arrazubi, Ana Custodio, Ana Fernández Montes, Marc Diez, Raquel Hernandez, María Luisa Limón, Juana María Cano, Rosario Vidal-Tocino, Ismael Macias, Laura Visa, Marta Martin Richard, Tamara Sauri, Cinta Hierro, Mireia Gil, Paula Cerda, Elia Martínez Moreno, Nieves Martínez Lago, Antonio José Mérida-García, Lucía Gómez González, Francisco Javier García Navalón, Maribel Ruiz Martín, Gema Marín, Flora López-López, Ana Belen Ruperez Blanco, Alejandro Francisco Fernández, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Felipe Alvarez-Manceñido

MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study

  • RESEARCH ARTICLE

Na Wang, Yuan Zhang, Junhua Wu, Yili Zhu, Ying Wu, Bo Huang, Ruiguang Zhang, Jun Fan, Xiu Nie

Insight into the significance of Foxp3 + tumor-infiltrating lymphocytes in squamous cell lung cancer

  • Open Access
  • RESEARCH ARTICLE

Kazu Shiomi, Masaaki Ichinoe, Ai Ushiwata, Koji Eshima, Ryo Nagashio, Shoko Hayashi, Dai Sonoda, Yasuto Kondo, Raito Maruyama, Masashi Mikubo, Yoshiki Murakumo, Yukitoshi Satoh

A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients

  • RESEARCH ARTICLE

Ranita Pal, Trisha Choudhury, Madhurima Ghosh, Manisha Vernakar, Partha Nath, Vilas Deorao Nasare

Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis

  • RESEARCH ARTICLE

Ying Wang, Yalan Sun, Fang Lu, Xianghong Zhao, Zhenlin Nie, Feng Zhu, Bangshun He

Impact of platinum-based chemotherapy on the tumor mutational burden and immune microenvironment in non-small cell lung cancer with postoperative recurrence

  • RESEARCH ARTICLE

Jianghua Wu, Wei Sun, Yanhui Zhang, Luning Mao, Tingting Ding, Xiaozheng Huang, Dongmei Lin

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

  • Open Access
  • RESEARCH ARTICLE

Helena Pla, Eudald Felip, Verónica Obadia, Sonia Pernas, Gemma Viñas, Mireia Margelí, Roser Fort-Culillas, Sonia Del Barco, Nuria Sabaté, Eduard Fort, Clara Lezcano, Beatriz Cirauqui, Vanesa Quiroga, Agostina Stradella, Miguel Gil Gil, Anna Esteve, Sabela Recalde

Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study

  • RESEARCH ARTICLE

Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang

Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis

  • RESEARCH ARTICLE

Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

  • RESEARCH ARTICLE

Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez Álvarez, Reyes Bernabé-Caro, Luis Chara, Marta López-Brea, Laia Vilà, Maria Ángeles Sala González, Anabel del Barrio Díaz Aldagalán, Beatriz Esteban Herrera, Rafael López Castro, Ruth Álvarez Cabellos, Marta Doménech, Sandra Falagan, Alberto Moreno Vega, Carlos Aguado, Andrés Barba, Maria Teresa Delgado Ureña, Dolores Isla, Lorena Bellido Hernández, José Luis Fírvida Pérez, Óscar Juan-Vidal, Bartomeu Massutí, Xabier Mielgo-Rubio, Ana Laura Ortega, Silvia Catot, Manuel Dómine, Corina Escoín-Pérez, Francisco García Navalón, Ignacio Gil-Bazo, Silvia Muñoz, Delvys Rodríguez-Abreu, Rosa María Villatoro Roldán, Guillermo Alonso-Jáudenes Curbera, Luis León-Mateos, Airam Padilla, Alfredo Paredes Lario, José Miguel Sánchez-Torres, Pilar Garrido

SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases

  • RESEARCH ARTICLE

María-Carmen Rubio Rodríguez, Xin Chen-Zhao, Ovidio Hernando, Sonia Flamarique, Pedro Fernández-Letón, Maider Campo, Mercedes López, Maitane Rodríguez, Daniel Zucca, Daniel Martínez, Emilio Sánchez-Saugar, Fernando Mañeru, Juan García Ruiz-Zorrilla, Paz García de Acilu, Jeannette Valero, Angel Montero, Raquel Ciérvide, Beatriz Alvarez, Mariola García-Aranda, Rosa Alonso, Miguel Angel de la Casa, Leyre Alonso, Mónica Nuñez, Jaime Martí, Fernando Arias

Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis

  • BRIEF RESEARCH ARTICLE

Jose C. Tapia, Javier Gavira, Georgia Anguera, Sofia Sanchez, Alejandra Romano, Freya Bosma, Alejandra Molina, Judit Sanz-Beltran, Cristina Martin-Lorente, Fernando Algaba, Pablo Maroto

Correction: Surgical margins and prognosis of borderline and malignant phyllodes tumors

  • Correction

Jialin Su, Shanling Liu, Gang Tu, Fangxuan Li, Jie Zhang, Lu Gan

Editorial Expression of Concern: miRNA signatures in childhood sarcomas and their clinical implications

  • Editorial Expression of Concern

G. M. Viera, K. B. Salomao, G. R. de Sousa, M. Baroni, L. E. A. Delsin, J. A. Pezuk, M. S. Brassesco

Neu im Fachgebiet Onkologie

Mehr Nierenkrebs bei regelmäßiger Einnahme von NSAR?

In der Allgemeinbevölkerung ist die wiederholte Verordnung von nichtsteroidalen Antirheumatika (NSAR) mit einem leicht erhöhten Nierenkrebsrisiko assoziiert. Dieses Ergebnis einer schwedischen Registerstudie ist allerdings mit einigen Fragezeichen zu versehen. 

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Folgetumoren nach TNBC sind oft Hormonrezeptor-positiv

Frauen mit triple-negativem Brustkrebs (TNBC) erhalten nach der Primärbehandlung üblicherweise keine chemopräventive endokrine Therapie verordnet. Folgt man den Ergebnissen einer Studie, könnte das vielleicht ein Fehler sein.

Zervixkarzinom-Screening: mit 65 Jahren Schluss?

Möglicherweise profitieren nicht alle Frauen über 65 Jahre von einer Fortsetzung des Screenings auf Gebärmutterhalskrebs. Aktuelle Modellrechnungen anhand von US-Daten legen nahe, wie eine Exit-Strategie aussehen könnte.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.